Skip to main content
SpringerLink
Log in

D-Hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management

  • Original Articles
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Alfacalcidol (1-alpha-hydroxyvitamin D3 is a non-endogenous analog of vitamin D which can bypass the renal and intestinal regulatory mechanisms that control the production of calcitriol (1,25-hydroxyvitamin D3, the active form of vitamin D, D-Hormone). Alfacalcidol may be metabolized into calcitriol with a limited risk of hypercalcemia. Alfacalcidol and calcitriol have been evaluated in animal and human studies assessing their effects on bone mineral density and fracture rates. More recently, they have been shown to produce beneficial effects in muscle, immune system, and autoimmune diseases, including rheumatoid arthritis. This paper discusses the therapeutic efficacy of alfacalcidol in reports in which it has been proposed as an interesting alternative to vitamin D or calcitriol. Some recent findings about general metabolism and regulation of vitamin D and its analogs are discussed. The biological and clinical effects of alfacalcidol in post-menopausal osteoporosis are reviewed, followed by critical appraisal of its efficacy in preventing bone loss and falls in the elderly. The last two sections discuss the role of D-analogs in regulating the immune system, with particular regard to rheumatoid arthritis. The main results of this review show that alfacalcidol may have a wider range of therapeutic applicability, beyond simply restricting it to patients in hemodialysis or peritoneal dialysis with high serum levels of intact PTH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stokstad E. Nutrition. The vitamin D deficit. Science 2003; 302: 1886–8.

    CAS  Google Scholar 

  2. Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science 1997; 277: 1827–30.

    Article  PubMed  CAS  Google Scholar 

  3. Fu GK, Portale AA, Miller WL. Complete structure of the human gene for the vitamin D 1 alpha-hydroxylase. P450c1alpha. DNA Cell Biol 1997; 16: 1499–507.

    Article  CAS  Google Scholar 

  4. St-Arnaud R, Arabian A, Travers R, et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000; 141: 2658–66.

    Article  PubMed  CAS  Google Scholar 

  5. Boyan BD, Sylvia VL, McKinney N, Schwartz Z. Membrane actions of vitamin D metabolites 1alpha,25(OH)2D3 and 24R,25(OH)2D3 are retained in growth plate cartilage cells from vitamin D receptor knockout mice. J Cell Biochem 2003; 90: 1207–23.

    Article  PubMed  CAS  Google Scholar 

  6. Tanaka H. Vitamin D metabolites and bone. In: Feldman D, Glorieux FH, Pike JW, eds. Vitamin D. Academic Press, San Diego 1997: 305–12.

    Google Scholar 

  7. Seo EG, Norman AW. Three-fold induction of renal 25-hydroxyvitamin D3-24-hydroxylase activity and increased serum 24,25-dihydroxyvitamin D3 levels are correlated with the healing process after chick tibial fracture. J Bone Miner Res 1997; 12: 598–606.

    Article  PubMed  CAS  Google Scholar 

  8. Carpenter TO, Keller M, Schwartz D, et al. 24,25 Dihydroxyvitamin D supplementation corrects hyperparathyroidism and improves skeletal abnormalities in X-linked hypophosphatemic ricketsa clinical research center study. J Clin Endocrinol Metab 1996; 81: 2381–8.

    Article  PubMed  CAS  Google Scholar 

  9. Jones G, Ramshaw H, Zhang A, et al. Expression and activity of vitamin D-metabolizing cytochrome P450s (CYP1alpha and CYP24) in human nonsmall cell lung carcinomas. Endocrinology 1999; 140: 3303–10.

    Article  PubMed  CAS  Google Scholar 

  10. Yamasaki T, Izumi S, Ide H, Ohyama Y. Identification of a novel rat microsomal vitamin D3 25-hydroxylase. J Biol Chem 2004; 279: 22848–56.

    Article  PubMed  CAS  Google Scholar 

  11. Gupta RP, Hollis BW, Patel SB, Patrick KS, Bell NH. CYP3A4 is a Human Microsomal Vitamin D 25-Hydroxylase. J Bone Miner Res 2004; 19: 680–8.

    Article  PubMed  CAS  Google Scholar 

  12. Kream BE, Reynolds RD, Knutson JC, Eisman JA, DeLuca HF. Intestinal cytosol binders of 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D. Arch Biochem Biophys 1976; 176: 779–87.

    Article  PubMed  CAS  Google Scholar 

  13. DeLuca HF. New concepts of vitamin D functions. Ann NY Acad Sci USA 1992; 669: 59–68.

    Article  CAS  Google Scholar 

  14. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003; 89: 552–72.

    Article  PubMed  CAS  Google Scholar 

  15. Ooms ME, Lips P, Roos JC, et al. Vitamin D status and sex hormone binding globulin: determinants of bone turnover and bone mineral density in elderly women. J Bone Miner Res 1995; 10: 1177–84.

    Article  PubMed  CAS  Google Scholar 

  16. Beckerman P, Silver J. Vitamin D and the parathyroid. Am J Med Sci 1999; 317: 363–9.

    Article  PubMed  CAS  Google Scholar 

  17. Lau KH, Baylink DJ. Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 1999; 65: 295–306.

    Article  PubMed  CAS  Google Scholar 

  18. Christakos S, Raval-Pandya M, Wernyj RP, Yang W. Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J 1996; 316 (Pt 2): 361–71.

    PubMed  CAS  Google Scholar 

  19. Kinyamu HK, Gallagher JC, Prahl JM, DeLuca HF, Petranick KM, Lanspa SJ. Association between intestinal vitamin D receptor, calcium absorption, and serum 1,25 dihydroxyvitamin D in normal young and elderly women. J Bone Miner Res 1997; 12: 922–8.

    Article  PubMed  CAS  Google Scholar 

  20. Hosseinpour F, Wikvall K. Porcine microsomal vitamin D(3) 25-hydroxylase (CYP2D25). Catalytic properties, tissue distribution, and comparison with human CYP2D6. J Biol Chem 2000; 275: 34650–5.

    CAS  Google Scholar 

  21. Hosseinpour F, Ibranovic I, Tang W, Wikvall K. 25-Hydroxylation of vitamin D3 in primary cultures of pig hepatocytes: evidence for a role of both CYP2D25 and CYP27A1. Biochem Biophys Res Commun 2003; 303: 877–83.

    Article  PubMed  CAS  Google Scholar 

  22. Ueno Y, Shinki T, Nagai Y, Murayama H, Fujii K, Suda T. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem 2003; 90: 267–77.

    Article  PubMed  CAS  Google Scholar 

  23. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004; 15: 49–60.

    Article  PubMed  CAS  Google Scholar 

  24. Alvarez-Hernandez D, Naves M, Santamaria I, Menarguez J, Torregrosa V, Cannata J. Response of parathyroid glands to calcitriol in culture: is this response mediated by the genetic polymorphisms in vitamin D receptor? Kidney Int Suppl 2003; 85: S19–22.

    Article  PubMed  CAS  Google Scholar 

  25. Slatopolsky E. Brown AJ. Vitamin D and its analogs in chronic renal failure. Osteoporos Int 1997; 7(Suppl 3): S202–8.

    Article  PubMed  Google Scholar 

  26. Ledger GA, Burritt MF, Kao PC, O’Fallon WM, Riggs BL, Khosla S. Abnormalities of parathyroid hormone secretion in elderly women that are reversible by short term therapy with 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1994; 79: 211–6.

    Article  PubMed  CAS  Google Scholar 

  27. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52: 3–9.

    Article  PubMed  CAS  Google Scholar 

  28. Gallacher SJ, Cowan RA, Fraser WD, Logue FC, Jenkins A, Boyle IT. Acute effects of intravenous 1 alpha-hydroxycholecalciferol on parathyroid hormone, osteocalcin and calcitriol in man. Eur J Endocrinol 1994; 130: 141–5.

    Article  PubMed  CAS  Google Scholar 

  29. Shiraishi A, Higashi S, Okawa H. The effect of 1-a(OH)D3 on bone metabolism in parathyroidectomized rats with continuous PTH perfusion. Osteoporos Int 1997; 7: 35.

    Article  Google Scholar 

  30. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev 1992; 13: 66–80.

    PubMed  CAS  Google Scholar 

  31. Lind L, Wengle B, Lithell H, Ljunghall S. Reduction in serum alkaline phosphatase levels by treatment with active vitamin D (alphacalcidol) in primary and secondary hyperparathyroidism and in euparathyroid individuals. Scand J Urol Nephrol 1991; 25: 233–6.

    Article  PubMed  CAS  Google Scholar 

  32. Somjen D, Weisman Y, Kaye AM. Pretreatment with 1,25(OH)2 vitamin D or 24,25(OH)2 vitamin D increases synergistically responsiveness to sex steroids in skeletal-derived cells. J Steroid Biochem Mol Biol 1995; 55: 211–7.

    Article  PubMed  CAS  Google Scholar 

  33. Long J, Liu P, Zhang Y, et al. Interaction effects between estrogen receptor alpha gene, vitamin D receptor gene, age, and sex on bone mineral density in Chinese. J Hum Genet 2003; 48: 514–9.

    Article  PubMed  CAS  Google Scholar 

  34. van Leeuwen JP, van den Bernd GJ, van Driel M, Buurman CJ, Pols HA. 24,25-Dihydroxyvitamin D(3) and bone metabolism. Steroids 2001; 66: 375–80.

    Article  PubMed  Google Scholar 

  35. Chen JT, Shiraki M, Hasumi K, et al. 1-alpha-Hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone 1997; 20: 557–62.

    Article  PubMed  CAS  Google Scholar 

  36. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998; 250: 776–81.

    Article  PubMed  CAS  Google Scholar 

  37. Cantorna MT, Woodward WD, Hayes CE, DeLuca HF. 1,25-di-hydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol 1998; 160: 5314–9.

    PubMed  CAS  Google Scholar 

  38. Zofkova I, Kancheva RL. The effect of 1,25(OH)2 vitamin D3 on CD4+/CD8+ subsets of T lymphocytes in postmenopausal women. Life Sci 1997; 61: 147–52.

    Article  PubMed  CAS  Google Scholar 

  39. Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004; 15: 301–10.

    Article  PubMed  CAS  Google Scholar 

  40. Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus plain vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 2005 (in press).

  41. Hayashi Y, Fujita T. Decrease of vertebral fracture in osteoporotics by administration of 1-alpha-hydroxy-vitamin D3. JBMM 1992; 10: 184–8.

    Article  Google Scholar 

  42. Menczel J. Foldes J. Steinberg R. et al. Alfacalcidol (alpha D3) and calcium in osteoporosis. Clin Orthop 1994; 300: 241–7.

    Google Scholar 

  43. Orimo H, Shiraki M, Hayashi Y, et al. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994; 54: 370–6.

    Article  PubMed  CAS  Google Scholar 

  44. Shiraki M, Kushida K, Yamazaki K, Nagai T, Ioue T, Orimo H. Effects of 2 years’ treatment of osteoporosis with la-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebocontrolled, double-blind prospective study. Endocr J 1996; 43: 211–20.

    Article  CAS  Google Scholar 

  45. Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999; 9: 75–81.

    Article  PubMed  CAS  Google Scholar 

  46. Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1a-hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurosurg Psychiatry 1999; 66: 64–8.

    Article  CAS  Google Scholar 

  47. Sato Y, Maruoka H, Oizumi K. Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1-a-hydroxyvitamin D3 and calcium supplementation. Stroke 1997; 28: 736–9.

    Article  PubMed  CAS  Google Scholar 

  48. Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J. Prevention of corticosteroid-induced osteoporosis by alphacalcidol. Z Rheumatol 2000; 59: 48–52.

    Article  PubMed  Google Scholar 

  49. Aloia JF. Role of calcitriol in the treatment of postmenopausal osteoporosis. Metabolism 1990; 39(4 Suppl 1): 35–8.

    Article  PubMed  CAS  Google Scholar 

  50. Ebeling PR, Wark JD, Yeung S, et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study. J Clin Endocrinol Metab 2001; 86: 4098–103.

    Article  PubMed  CAS  Google Scholar 

  51. Sambrook P, Henderson NK, Keogh A, et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000; 15: 1818–24.

    Article  PubMed  CAS  Google Scholar 

  52. Gallagher JC, Riggs BL, Recker RR, Goldgar D. The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 1989; 191: 287–92.

    Article  PubMed  CAS  Google Scholar 

  53. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 1990; 113: 649–55.

    Article  CAS  Google Scholar 

  54. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001; 86: 3618–28.

    Article  PubMed  CAS  Google Scholar 

  55. Lambrinoudaki I, Chan DT, Lau CS, Wong RW, Yeung SS, Kung AW. Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. J Rheumatol 2000; 27: 1759–65.

    CAS  Google Scholar 

  56. Sambrook P. Alfacalcidol and calcitriol in the prevention of bone loss after organ transplantation. Calcif Tissue Int 1999; 65: 341–3.

    Article  PubMed  CAS  Google Scholar 

  57. Hedstrom M. Hip fracture patients, a group of frail elderly people with low bone mineral density, muscle mass and IGF-I levels. Acta Physiol Scand 1999; 167: 347–50.

    Article  PubMed  CAS  Google Scholar 

  58. Ritz E, Boland R, Kreusser W. Effects of vitamin D and parathyroid hormone on muscle: potential role in uremic myopathy. Am J Clin Nutr 1980; 33: 1522–9.

    PubMed  CAS  Google Scholar 

  59. Pleasure D, Wyszynski B, Sumner A, et al. Skeletal muscle calcium metabolism and contractile force in vitamin D-deficient chicks. J Clin Invest 1979; 64: 1157–67.

    Article  PubMed  CAS  Google Scholar 

  60. Curry OB, Basten JF, Francis MJ, Smith R. Calcium uptake by sarcoplasmic reticulum of muscle from vitamin D-deficient rabbits. Nature 1974; 249: 83–4.

    Article  PubMed  CAS  Google Scholar 

  61. Curry O, Francis MJ, Smith R. Proceedings: The effects of vitamin D deficiency on the isolated sarcoplasmic reticulum of muscle. Clin Sci Mol Med 1974; 46: 7P.

    Google Scholar 

  62. Stroder J. Hypothyroidism and rachitis. Arch Kinderheilkd [Archives of Pediatrics] 1965; 173: 105–9.

    CAS  Google Scholar 

  63. Bischoff HA, Borchers M, Gudat F, et al. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 2001; 33: 19–24.

    Article  PubMed  CAS  Google Scholar 

  64. Bischoff HA, Stahelin HB, Tyndall A, Theiler R. Relationship between muscle strength and vitamin D metabolites: are there therapeutic possibilities in the elderly? Z Rheumatol 2000; 59(Suppl 1): 39–41.

    Article  PubMed  Google Scholar 

  65. Bischoff HA, Stahelin HB, Urscheler N, et al. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 1999; 80: 54–8.

    Article  PubMed  CAS  Google Scholar 

  66. Rimaniol JM, Authier FJ, Chariot P. Muscle weakness in intensive care patients: initial manifestation of vitamin D deficiency. Intensive Care Med 1994; 20: 591–2.

    Article  PubMed  CAS  Google Scholar 

  67. Buitrago C, Vazquez G, De Boland AR, Boland R. The vitamin D receptor mediates rapid changes in muscle protein tyrosine phosphorylation induced by 1,25(OH)(2)D(3). Biochem Biophys Res Commun 2001; 289: 1150–6.

    Article  PubMed  CAS  Google Scholar 

  68. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88: 5766–72.

    Article  PubMed  CAS  Google Scholar 

  69. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41: 105–12.

    Article  PubMed  CAS  Google Scholar 

  70. Ziambaras K, Dagogo-Jack S. Reversible muscle weakness in patients with vitamin D deficiency. West J Med 1997; 167: 435–9.

    PubMed  CAS  Google Scholar 

  71. Grady D, Halloran B, Cummings S, et al. 1,25-Dihydroxyvitamin D3 and muscle strength in the elderly: a randomized controlled trial. J Clin Endocrinol Metab 1991; 73: 1111–7.

    Article  PubMed  CAS  Google Scholar 

  72. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124: 400–6.

    Article  CAS  Google Scholar 

  73. Glerup H, Mikkelsen K, Poulsen L, et al. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int 2000; 66: 419–24.

    Article  PubMed  CAS  Google Scholar 

  74. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000; 15: 1113–8.

    Article  PubMed  CAS  Google Scholar 

  75. Bischoff H, Stahelin H, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003; 18: 343–51.

    Article  PubMed  CAS  Google Scholar 

  76. Dukas L, Bischoff HA, Lindpaintner LS, et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004; 52: 230–6.

    Article  PubMed  Google Scholar 

  77. Janssen HC, Samson MM, Verhaar HJ. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 2002; 75: 611–5.

    PubMed  CAS  Google Scholar 

  78. O’Kelly J, Hisatake J, Hisatake Y, Bishop J, Norman A, Koeffler HP. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J Clin Invest 2002; 109: 1091–9.

    PubMed  Google Scholar 

  79. Towers TL, Freedman LP. Granulocyte-macrophage colonystimulating factor gene transcription is directly repressed by the vitamin D3 receptor. Implications for allosteric influences on nuclear receptor structure and function by a DNA element. J Biol Chem 1998; 273: 10338–48.

    CAS  Google Scholar 

  80. DeLuca HF. Cantorna MT. Vitamin D: Its role and uses in immunology. FASEB J 2001; 15: 2579–85.

    CAS  Google Scholar 

  81. Lemire JM. Immunomodulatory actions of 1.25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 1995; 53: 599–602.

    Article  PubMed  CAS  Google Scholar 

  82. Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995; 125(Suppl 6): 1704S–8S.

    PubMed  CAS  Google Scholar 

  83. Gardon E, Sindji L, Nataf S, Brachet P, Darcy F, Montero-Menei CN. Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta Neuropathol (Berl) 2003; 105: 438–48.

    Google Scholar 

  84. Oelzner P, Muller A, Deschner F, et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998; 62: 193–8.

    Article  PubMed  CAS  Google Scholar 

  85. Vaisberg MW, Kaneno R, Franco MF, Mendes NF. Influence of cholecalciferol (vitamin D3) on the course of experimental systemic lupus erythematosus in F1 (NZBxW) mice. J Clin Lab Anal 2000; 14: 91–6.

    Article  PubMed  CAS  Google Scholar 

  86. Zella JB, DeLuca HF. Vitamin D and autoimmune diabetes. J Cell Biochem 2003; 88: 216–22.

    Article  PubMed  CAS  Google Scholar 

  87. Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003; 17: 2386–92.

    Article  PubMed  CAS  Google Scholar 

  88. Demoor-Fossard M, Galera P, Santra M, Iozzo RV, Pujol JP, Redini F. A composite element binding the vitamin D receptor and the retinoic X receptor alpha mediates the transforming growth factor-beta inhibition of decorin gene expression in articular chondrocytes. J Biol Chem 2001; 276: 36983–92.

    Article  PubMed  CAS  Google Scholar 

  89. Tanaka H, Abe E, Miyaura C, et al. 1 alpha,25-Dihydroxyc-holecalciferol and a human myeloid leukaemia cell line (HL-60). Biochem J 1982; 204: 713–9.

    PubMed  CAS  Google Scholar 

  90. Wiese RJ, Uhland-Smith A, Ross TK, Prahl JM, DeLuca HF. Upregulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992; 267: 20082–6.

    PubMed  CAS  Google Scholar 

  91. Yamauchi Y, Tsunematsu T, Konda S, Hoshino T, Itokawa Y, Hoshizaki H. A double blind trial of alfacalcidol on patients with rheumatoid arthritis (RA). Ryumachi [official journal of the Japan Rheumatism Association] 1989; 29: 11–24.

    CAS  Google Scholar 

  92. Yang S, Smith C, Prahl JM, Luo X, DeLuca HF. Vitamin D deficiency suppresses cell-mediated immunity in vivo. Arch Biochem Biophys 1993; 303: 98–106.

    Article  PubMed  CAS  Google Scholar 

  93. Yang S, Smith C, DeLuca HF. 1 alpha, 25-Dihydroxyvitamin D3 and 19-nor-1 alpha, 25-dihydroxyvitamin D2 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo. Biochem Biophys Acta 1993; 1158: 279–86.

    Article  PubMed  CAS  Google Scholar 

  94. Kameda H, Takeuchi T. Osteoporosis associated with rheumatoid arthritis. Nippon Rinsho [Japonese Journal of Clinical Medicine] 2003; 61: 292–8.

    Google Scholar 

  95. Haugeberg G, Orstavik RE, Kvien TK. Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol 2003; 15: 469–75.

    Article  PubMed  Google Scholar 

  96. Brosch S, Redlich K, Pietschmann P. [Pathogenesis of osteoporosis in rheumatoid arthritis]. Acta Med Austriaca 2003; 30: 1–5.

    Article  PubMed  Google Scholar 

  97. Hirayama T, Danks L, Sabokbar A, Athanasou NA. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology (Oxf) 2002; 41: 1232–9.

    Article  CAS  Google Scholar 

  98. Sugiyama T. Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis. J Bone Miner Metab 2001; 19: 89–96.

    Article  PubMed  CAS  Google Scholar 

  99. Joe B, Griffiths MM, Remmers EF, Wilder RL. Animal models of rheumatoid arthritis and related inflammation. Curr Rheumatol Rep 1999; 1: 139–48.

    Article  PubMed  CAS  Google Scholar 

  100. Yilmaz M, Kendirli SG, Altintas D, Bingol G, Antmen B. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol 2001; 20: 30–5.

    Article  PubMed  CAS  Google Scholar 

  101. E, Perniok A, Becker A, Feldkamp J. Effect of 1alpha,25(OH)2-vitamin D3 on TNF alpha-mediated apoptosis of human primary osteoblast-like cells in vitro. Horm Metab Res 1999; 31: 653–6.

    Article  Google Scholar 

  102. Bottcher J, Malich A, Pfeil A, et al. Potential clinical relevance of digital radiogrammetry for quantification of periarticular bone demineralization in patients suffering from rheumatoid arthritis depending on severity and compared with DXA. Eur Radiol 2004; 14: 631–7.

    Article  PubMed  CAS  Google Scholar 

  103. Goertz B, Fassbender WJ, Williams JC, et al. Vitamin D receptor genotypes are not associated with rheumatoid arthritis or biochemical parameters of bone turnover in German RA patients. Clin Exp Rheumatol 2003; 21: 333–9.

    PubMed  CAS  Google Scholar 

  104. Lee CK, Hong JS, Cho YS, Yoo B, Kim GS, Moon HB. Lack of relationship between vitamin D receptor polymorphism and bone erosion in rheumatoid arthritis. J Korean Med Sci 2001; 16: 188–92.

    PubMed  CAS  Google Scholar 

  105. Gough A, Sambrook P, Devlin J, et al. Effect of vitamin D receptor gene alleles on bone loss in early rheumatoid arthritis. J Rheumatol 1998; 25: 864–8.

    PubMed  CAS  Google Scholar 

  106. Lisker R, Lopez MA, Jasqui S, et al. Association of vitamin D receptor polymorphisms with osteoporosis in Mexican post-menopausal women. Hum Biol 2003; 75: 399–403.

    Article  PubMed  Google Scholar 

  107. Ravid A, Koren R, Maron L, Liberman UA. 1,25(OH)2D3 increases cytotoxicity and exocytosis in lymphokine-activated killer cells. Mol Cell Endocrinol 1993; 96: 133–9.

    Article  PubMed  CAS  Google Scholar 

  108. Rau R. Use of glucocorticoids in rheumatoid arthritis. Inhibition of disease progression versus risk of steroid osteoporosis. Z Rheumatol [German Journal of Rheumatology] 2001; 60: 485–91.

    CAS  Google Scholar 

  109. Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 2002; 46: 3136–42.

    Article  PubMed  Google Scholar 

  110. Reginster JY, de Froidmont C, Lecart MP, Sarlet N, Defraigne JO. Alphacalcidol in prevention of glucocorticoid-induced osteoporosis. Calcif Tissue Int 1999; 65: 328–31.

    Article  PubMed  CAS  Google Scholar 

  111. Yudoh K, Matsuno H, Osada R, Nakazawa F, Katayama R, Kimura T. Decreased cellular activity and replicative capacity of osteoblastic cells isolated from the periarticular bone of rheumatoid arthritis patients compared with osteoarthritis patients. Arthritis Rheum 2000; 43: 2178–88.

    Article  PubMed  CAS  Google Scholar 

  112. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev 1998; 19: 55–79.

    Article  PubMed  CAS  Google Scholar 

  113. Ohlsson C, Vidal O. Effects of growth hormone and insulin-like growth factors on human osteoblasts. Eur J Clin Invest 1998; 28: 184–6.

    Article  PubMed  CAS  Google Scholar 

  114. Toyoda T, Inokuchi S, Saito S, Horie Y, Tomita S. Bone loss of the radius in rheumatoid arthritis. Comparison between 34 patients and 40 controls. Acta Orthop Scand 1996; 67: 269–73.

    Article  CAS  Google Scholar 

  115. Lee S, Szlachetka M, Christakos S. Effect of glucocorticoids and 1,25-dihydroxyvitamin D3 on the developmental expression of the rat intestinal vitamin D receptor gene. Endocrinology 1991; 129: 396–401.

    Article  PubMed  CAS  Google Scholar 

  116. Godschalk M, Levy JR, Downs RW, Jr. Glucocorticoids decrease vitamin D receptor number and gene expression in human osteosarcoma cells. J Bone Miner Res 1992; 7: 21–7.

    Article  PubMed  CAS  Google Scholar 

  117. Blotta MH, DeKruyff RH, Umetsu DT. Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol 1997; 158: 5589–95.

    PubMed  CAS  Google Scholar 

  118. Schacht E. Osteoporosis in rheumatoid arthritis-significance of alfacalcidol in prevention and therapy. Z Rheumatol [German Journal of Rheumatology] 2000; 59(Suppl 1): 10–20.

    Article  Google Scholar 

  119. McKnight AJ, Zimmer GJ, Fogelman I, Wolf SF, Abbas AK. Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol 1994; 152: 2172–9.

    PubMed  CAS  Google Scholar 

  120. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O’Garra A. 1alpha,25-Dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974–80.

    PubMed  CAS  Google Scholar 

  121. Andjelkovic Z, Vojinovic J, Pejnovic N, et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999; 17: 453–6.

    PubMed  CAS  Google Scholar 

  122. Brohult J, Jonson B. Effects of large doses of calciferol on patients with rheumatoid arthritis. A double-blind clinical trial. Scand J Rheumatol 1973; 2: 173–6.

    Article  CAS  Google Scholar 

  123. Dottori L, D’Ottavio D, Brundisini B. Calcifediol and calcitonin in the therapy of rheumatoid arthritis. A short-term controlled study. Minerva Med 1982; 73: 3033–40.

    CAS  Google Scholar 

  124. Yamauchi Y, Tsunematsu T, Honda S, Hoshino T, Itokawa Y. A double blind trial of alfacalcidol on patients with rheumatoid arthritis (RA). Ryumachi [Official Journal of the Japan Rheumatism Association] 1989; 29: 11–24.

    CAS  Google Scholar 

  125. Hein G, Oelzner P. Vitamin D metabolites in rheumatoid arthritis: findings—hypotheses—consequences. Z Rheumatol [German Journal of Rheumatology] 2000; 59(Suppl 1): 28–32.

    Article  Google Scholar 

  126. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 961–8.

    Article  CAS  Google Scholar 

  127. Gukasian DA, Nasonov EL, Balabanova RM, Smirnov AV, Vlasova IS. Effects of alfacalcidol on mineral density of bone tissue in patients with rheumatoid arthritis. Klin Med [Clinical Medicine] 2001; 79: 47–50.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Public Health, Epidemiology and Health Economics Unit, Faculty of Medicine, University of Liège, Sart-Tilman, Belgium

    Florent Richy PhD, Marie-Paule Lecart, Linda Hanssens, Audrey Mawet & Jean-Yves Reginster

  2. Bone and Cartilage Metabolism Research Unit, University Hospital, Liège, Belgium

    Rita Deroisy, Marie-Paule Lecart & Jean-Yves Reginster

  3. WHO Collaborating Center for the Public Health Aspects of Osteoarticular Disorders, Liège, Belgium

    Florent Richy PhD, Marie-Paule Lecart, Linda Hanssens, Audrey Mawet & Jean-Yves Reginster

Authors
  1. Florent Richy PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rita Deroisy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marie-Paule Lecart
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Linda Hanssens
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Audrey Mawet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-Yves Reginster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florent Richy PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richy, F., Deroisy, R., Lecart, MP. et al. D-Hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clin Exp Res 17, 133–142 (2005). https://doi.org/10.1007/BF03324586

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03324586

Keywords

Search

Navigation